InnoCan Pharma Dividend

Dividend criteria checks 0/6

InnoCan Pharma does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.4%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-CA$0.017
Dividend yield forecast in 3Y	n/a

Recent dividend updates

No updates

Recent updates

It's Probably Less Likely That InnoCan Pharma Corporation's (CSE:INNO) CEO Will See A Huge Pay Rise This Year

May 04

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if INNO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if INNO's dividend payments have been increasing.

Dividend Yield vs Market

InnoCan Pharma Dividend Yield vs Market

How does INNO dividend yield compare to the market?
Segment	Dividend Yield
Company (INNO)	n/a
Market Bottom 25% (CA)	1.9%
Market Top 25% (CA)	6.4%
Industry Average (Pharmaceuticals)	2.4%
Analyst forecast in 3 Years (INNO)	n/a

Notable Dividend: Unable to evaluate INNO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate INNO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate INNO's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as INNO has not reported any payouts.

InnoCan Pharma Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

It's Probably Less Likely That InnoCan Pharma Corporation's (CSE:INNO) CEO Will See A Huge Pay Rise This Year

Full year 2023 earnings released: US$0.018 loss per share (vs US$0.015 loss in FY 2022)

InnoCan Pharma Corporation announced that it has received CAD 1.98821 million in funding

InnoCan Pharma Corporation, Annual General Meeting, May 09, 2024

InnoCan Pharma Corporation announced that it expects to receive CAD 3 million in funding

Third quarter 2023 earnings released: US$0.008 loss per share (vs US$0.001 loss in 3Q 2022)

InnoCan Pharma Corporation announced that it has received CAD 1.627682 million in funding

InnoCan Pharma Corporation announced that it expects to receive CAD 3 million in funding

InnoCan Pharma Corporation Announces Appointment of Dr. Joseph V. Pergolizzi to its Scientific Advisory Board

Second quarter 2023 earnings released: US$0.002 loss per share (vs US$0.007 loss in 2Q 2022)

InnoCan Pharma Corporation announced that it has received CAD 1.934239 million in funding

New minor risk - Shareholder dilution

InnoCan Pharma Corporation announced that it expects to receive CAD 1.934239 million in funding

New minor risk - Shareholder dilution

InnoCan Pharma Corporation announced that it has received CAD 3.9606 million in funding

Innocan Pharma Corporation Submits New Patent Applications for Advanced Pain Relief Technology

First quarter 2023 earnings released: US$0.005 loss per share (vs US$0.003 loss in 1Q 2022)

InnoCan Pharma Corporation Announces Successful Treatment of Billy with Liposomal-CBD Injection in Pre-Clinical Trial

Full year 2022 earnings released: US$0.015 loss per share (vs US$0.045 loss in FY 2021)

InnoCan Pharma Corporation announced that it has received CAD 0.4955 million in funding

Is InnoCan Pharma (CSE:INNO) In A Good Position To Deliver On Growth Plans?

Third quarter 2022 earnings released: US$0.001 loss per share (vs US$0.016 loss in 3Q 2021)

Innocan Pharma Corporation Announces the Addition of Givi Topchishvili, to Advisory Committee, as A Business Strategy Adviser

Less than half of directors are independent

Innocan Pharma Corporation Announces Additional Positive Results in New Preclinical Trial Involving A Dog with Refractory Epilepsy

Second quarter 2022 earnings released

InnoCan Pharma Corporation Meets Pre-Clinical End-Point in Pilot Pain Study on Dogs Using LPT Liposome Technology

We Think InnoCan Pharma (CSE:INNO) Can Afford To Drive Business Growth

InnoCan Pharma Corporation Announces Results Approaches 100% Bioavailability Following Subcutaneous Injection of Its CBD Proprietary LPT Delivery System in A Clinical Study Conducted on Dogs Suffering from Pain

InnoCan Pharma Corporation Files PCT Patent Application for Novel Composition for Preventing and Treating Hair Loss

Innocan Pharma Corporation Files PCT Patent Application for Diabetic Symptoms

InnoCan Pharma Corporation Reports Positive Results from Recent Preclinical Trial on Epileptic Seizures on Dog Using LPT

Innocan Pharma Corporation Reports Successful Preclinical Dog-Trial Results Regarding Pain Management

Innocan Pharma Corporation Announces Filing of PCT Patent Application for Vaginal Atrophy Treatment

First quarter 2022 earnings released

Less than half of directors are independent

Companies Like InnoCan Pharma (CSE:INNO) Are In A Position To Invest In Growth

InnoCan Pharma Corporation Reports Successful FDA Required Characterization of Highly CBD Loaded Liposome Platform

Is InnoCan Pharma (CSE:INNO) In A Good Position To Deliver On Growth Plans?

Innocan Pharma Corporation Cbd Integrated Anti-Aging Sleeping Mask Demonstrates A Reduction of the Appearance of Wrinkles by Up to 28.8% in 4 Weeks of Clinical Study

Innocan Pharma Corporation Completes a Cosmetic Clinical Study of SHIR® CBD Eye Serum on 22 Volunteers

Innocan Pharma Announces Patent Application for Novel Cannabis-Based Vaginal Moisturizer and Lubricant Treatment

Innocan Pharma's Liposome Platform Technology Demonstrates a 7-Week Prolonged Release of CBD into Bloodstream in Recent Animal Study

Innocan Pharma's CBD Loaded Liposome Platform Technology Receives Positive Results from Recent Animal Study

We Think InnoCan Pharma (CSE:INNO) Needs To Drive Business Growth Carefully

Innocan Pharma Announces Patent Application for Novel Cannabis-Based Anti-Itch Treatment

InnoCan Pharma Corporation Announces the Completion of Its First Full-Scale Manufacturing Run in the US and the Launching of Its US Commercial Online Platform

Innocan Pharma Announces Successful Production of CBD Loaded Liposomes Under Aseptic Conditions

New 90-day high: CA$0.41

InnoCan Pharma Corporation Announces Successful Completion of a Large-Scale Production of Exosomes

InnoCan Pharma Corporation announced that it has received CAD 2.367804 million in funding

New 90-day high: CA$0.31

InnoCan Pharma Corporation Announces the Completion of Its First Full-Scale Manufacturing Run in Europe and the Commencement of its Full-Scale Manufacturing Run in the USA

Innocan Pharma Corporation Announces the Launch of Two Therapeutic Studies on Small and Large Animals Examining the Therapeutic Efficacy of CBD Loaded Liposome Platform Technology in Relevant Diseases

New 90-day high: CA$0.30

Innocan Pharma's Clinical Study in the US Indicates That More Than 90% of Participants Experienced Pain Reduction After Using Innocan's Relief & Go OTC Pain Relief Spray

Innocan Pharma's Cosmetic Clinical Study Indicates a 90% Wrinkle Reduction After Using Its SHIR(TM) Premium CBD Facial Serum

Innocan Pharma Corporation Provides Clinical Update of its Unique CBD-Loaded Liposome Platform Technology for Injectable CBD

New 90-day high: CA$0.24

InnoCan Pharma Corporation Completes Successful Cosmetic Clinical Studies

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies